ClinicalTrialsFinder
RecruitingNot ApplicableNCT05149625

Comparison of the Efficacy and Satisfaction of Blood Glucose Management Between Continuous Glucose Monitoring Versus Traditional Self-blood Glucose Measurement in Diabetic Patients After Pancreatectomy

Comparison of the Efficacy and Satisfaction of Blood Glucose Management Between Continuous Glucose Monitoring Versus Traditional Self-blood Glucose Measurement in Diabetic Patients After Pancreatectomy : A Randomized Controlled Open Labeled Trial

Sponsor

Seoul National University Hospital

Enrollment

172 participants

Start Date

Nov 27, 2022

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus

Summary

This study aims to compare the efficacy and satisfaction of blood glucose management between continuous glucose monitoring versus traditional self blood glucose measurement in diabetic patients after pancreatectomy.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Dexcom G6 for people with diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDexcom G6

continuous glucose monitoring device

Locations(1)

Department of Surgery, Seoul National University College of Medicine

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05149625

Related Trials

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT070111472 locations

Swiss Diabetes Registry - SwissDiab Study

NCT011798154 locations

Genetic Studies of Insulin and Diabetes

NCT000019871 location

Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

NCT058808101 location

Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin

NCT076214192 locations